Is Roche/RHHBY an under-performing stock? Is Agilent overpriced?

these four are signficant players in the genome sequencing market, but RHHB stock price hasn't take off in the same way, and Agilent is way out in front.

Does this make RHHB a good buy, or, is there something wrong, and making the others a better prospect? Is Agilent a sell?